Anvirzel^TMregulates cell death through inhibiting GSK-3 activity in human U87 glioma cells

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cardiac glycosides show anti-cancer potential by inhibiting cancer cell proliferation and inducing apoptosis or autophagy.
• Anvirzel™ contains oleandrin and oleandrigenin, two toxic cardiac glycosides with potential anti-cancer applications.

Purpose of the Study:

• To investigate the signaling pathways involved in the differential cell death induced by Anvirzel™ in U87 human glioblastoma cells.
• To assess the anti-proliferative and anti-migratory effects of Anvirzel™ on U87 cells.

Main Methods:

• U87 cells were treated with varying doses of Anvirzel™ (10-250 μg/ml).
• Cell proliferation was measured using the WST-1 assay.
• Cell migration was assessed via wound healing assay.
• Protein expression related to cell death was analyzed using Western blot.

Main Results:

• Anvirzel™ significantly inhibited U87 cell growth in a time- and dose-dependent manner (24h and 48h treatments).
• Anvirzel™ treatment led to the inhibition of GSK-3, NOS, and HIF1-α protein expressions.
• Anvirzel™ treatment resulted in the activation of ERK signaling pathway in U87 cells.

Conclusions:

• Anvirzel™ exhibits anti-proliferative and anti-migratory effects on U87 glioblastoma cells.
• The compound appears to regulate cell death through mechanisms distinct from classical apoptosis.
• Further research is needed to fully elucidate the mechanistic insights into Anvirzel™'s cell death signaling pathways.